Notice of Presentation of Research Results on Dual CAR-eNK Cells for Glioblastoma at the iPSC 20th Anniversary Symposium | HEALIOS K.K. (4593) timely disclosure

Worth reading

51Recurring

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Neutral

Direction inferred from the company’s description.

Scale

—

Displayed only when the document provides numerical figures.

Wording

Definitive

How definitive the wording is.

Announced details

Dual CAR-eNK® cells; eNK® cells (development code: AKT-01/HLCN061)

Applicable field (uses covered by this announcement)

Glioblastoma; brain tumors; cancer immunocellular therapy

Launch date20 October 2026 (scheduled; poster presentation of research results)

Relationship between the counterparty and the company

HEALIOS K.K.4593

Relationship with the Company

Akatsuki Therapeutics Co., Ltd. is the development partner. National University Corporation Kyushu University is the joint research partner for brain tumors using CAR-eNK® cells.

CounterpartyAkatsuki Therapeutics Co., Ltd.; National University Corporation Kyushu University

Akatsuki Therapeutics Co., Ltd. is the development partner. National University Corporation Kyushu University is the joint research partner for brain tumors using CAR-eNK® cells. Other information on the location, representative, capital, and year established is Not disclosed.

Location (as indicated in this announcement)

Kyoto International Conference Center (presentation venue); HEALIOS K.K. Kobe Research Institute (presenter's affiliation)

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Announced details
Item	Details
Names of Products / Services Covered	Dual CAR-eNK® cells; eNK® cells (development code: AKT-01/HLCN061)
Counterparty	Akatsuki Therapeutics Co., Ltd.; National University Corporation Kyushu University
Counterparty overview	Akatsuki Therapeutics Co., Ltd. is the development partner. National University Corporation Kyushu University is the joint research partner for brain tumors using CAR-eNK® cells. Other information on the location, representative, capital, and year established is Not disclosed.
Relationship with the Company	Akatsuki Therapeutics Co., Ltd. is the development partner. National University Corporation Kyushu University is the joint research partner for brain tumors using CAR-eNK® cells.
Launch date	20 October 2026 (scheduled; poster presentation of research results)
Applicable area	Glioblastoma; brain tumors; cancer immunocellular therapy
Location	Kyoto International Conference Center (presentation venue); HEALIOS K.K. Kobe Research Institute (presenter's affiliation)

Items this document does not state (11)

Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleQuantitative EffectsUsage historyImpact on Business PerformanceSource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To present research results at the iPSC 20th Anniversary Symposium.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.